Ains-A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted. Methods Conclusion-Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.
Pterygium is a triangular sheet of fibrovascular tissue that invades the clear cornea from the bulbar conjunctiva, and has a high recurrence rate after simple excisionl-3 unless any adjunctive treatment is applied. The use of postoperative a irradiation renders a lower incidence of recurrence but may lead to complications such as scleral ulceration, infection, and cataract. 4 Other effective treatments such as the use of topical thiotepa can cause depigmentation of the lids,5 6 and postoperative topical mitomycin C has been associated with serious ocular complications. 7 We studied the efficacy and toxicity of intraoperative mitomycin C in the treatment of primary pterygium in a randomised, prospective, double blind, placebo controlled study comparing standard excision with excision and a single intraoperative application of mitomycin C.
Patients and methods A total of 66 consecutive primary pterygia were surgically excised in 54 patients between September 1992 and August 1993. A complete ocular examination, photographic documentation of the pterygium, and haematological examination (complete cell counts with differential, sedimentation rate, electrolytes, prothrombin time, and prothrombin thromboplastin time) were performed for each patient. The inclusion criteria were (1) age older than 20 years, (2) primary pterygium which invaded more than 2 mm into the cornea. Exclusion criteria were (1) external ocular diseases such as Sjogren syndrome and ocular rosacea, (2) USA) soaked in a solution of 0-1 mg/ml of mitomycin C or in distilled water for eyes in the control group, (8) the site was irrigated copiously with 20 ml of a saline solution after removal of the sponge, (9) no conjunctival sutures were used, (10) instillation of topical eyedrops of 0 1O% dexamethasone and gentamicin ointment followed by eye patching. Oral analgesics (paracetamol every 8 hours) were given to relieve postoperative pain.
Mitomycin C was present in a blue-violet crystalline powder that was reconstituted and diluted in sterile water just before surgery.
All the pterygia were evaluated on postoperative days 1, 7, 15 , and monthly thereafter by one of us (JCP) who was masked to the patient's treatment status. All patients had a repeat haematological examination on postoperative day 7, and periodic ocular photographic documentation was obtained. A total of 12 patients with bilateral pterygium were In a previous experimental study of the effects of mitomycin C on cultured rabbit subconjunctival fibroblasts, the authors found that its antiproliferative effect is both dose and time dependent.16 Other in vitro studies have shown that the effect of 5 minute exposure with mitomycin C at a concentration of 0*1 mg/ml to human Tenon's capsule fibroblasts results in a significant long term inhibition of fibroblast proliferation. At this dose, the number of cells did not increase more than 2-5 times to the density at day 0 during a 36 day period of the experiment, despite stimulation throughout this period with 10% fetal bovine serum. In contrast, at a concentration of 1 mg/ml more than 65% of the cells died.17
However, there are limitations in applying results of in vitro studies to the in vivo situation. The action of a drug over a monolayer of cells with relatively small amounts of extracellular matrix, and where most of the cells are proliferating may be different from the in vivo situation where cells are surrounded by connective tissue, which may impede drug penetration. Nevertheless, at the time of conjunctival surgery there are several growth factors, such as platelet derived growth factor (PDGF), that are released and might play an important role in pterygium recurrence. If the process is impaired even at this early stage, the ability of the fibroblast to proliferate as well as the capillaries to grow may be impaired.
The use of mitomycin C eyedrops in the postoperative period of pterygium surgery, in both doses, 0-2 and 04 mg/ml, four times daily for [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] days has been effective in reducing the recurrence rate of pterygium between OO/O-9O/O.l8-20 However, in a recent report this postoperative treatment has been related to serious ocular complications such as secondary glaucoma, comeal oedema, comeal perforation, iritis, sudden onset mature cataract, and scleral calcification.7 In contrast, no serious complications have been noted in another study2' with the postoperative use of 0 1 mg/ml mitomycin C twice daily for 5 days (with a mean follow up period of 15-3 months) or in the intraoperative mitomycin C treated eyes of our current study. A common element in toxicity with mitomycin C is a relatively large cumulative dose.7 22 Therefore, we consider that a single intraoperative exposure to mitomycin C would reduce the complication rate of mitomycin C eyedrop regimen.
Although serious complications with low concentrations of mitomycin C are rare, we noted in our study only minor complications. Delayed epithelial closure as a side effect of mitomycin C may predispose to postoperative infectious scleritis and endophthalmitis, particularly in tropical countries. None of the complications of mitomycin C treated eyes presented in Table 2 significantly troubled the patients. Moreover, conjunctival granulomas were found to be less frequent among the mitomycin C group than among the control group.
Recurrence of pterygium commonly occurs within 6 months after the initial surgery23 and the minimum follow up in our study has been 12 months. However, there are late complications such as scleromalacia related to the use of topical mitomycin C.24 Therefore, it is necessary to continue to assess the eyes treated with mitomycin C after this period. We have shown that the single intraoperative exposure to mitomycin C (0 1 mg/ml) reduces the recurrence rate of primary pterygium without serious complications over a mean follow up of 14 1 months. We suggest that the single intraoperative exposure of mitomycin C appears to be a safe, simple, effective, and useful form of adjunctive therapy to the surgical treatment of the primary pterygium.
